INC Research Announces Multi-Year Strategic Clinical Development Alliance with Astellas
(Thomson Reuters ONE) -
FSP alliance outsources highly specialized tasks across drug development
pipeline to drive global consistency and deliver significant time and cost
savings
Raleigh, N.C., April 17, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, announced today that the Company has entered into a Functional
Service Provider (FSP) alliance with Astellas Pharma Global Development,
Inc.(Astellas), to drive global consistency, save time and reduce costs for
multiple clinical development programs across several therapeutic areas. In an
initial three-year agreement, INC Research will deliver key functional services
to Astellas, including Clinical Monitoring, Clinical Data Management, Trial
Master File Management, Site Start-up and Study Feasibility activities. Work
began April 2 and is being conducted globally.
"INC Research has worked with Astellas on several full-service development
programs where our teams have created strong bonds and deep level of trust, and
we are excited to extend that relationship through our FSP alliance," said James
Ogle, CEO, INC Research. "With mutually agreed expectations and insight into
Astellas' development pipeline, our dedicated teams will utilize our innovative
tools and proprietary processes to efficiently manage these clinical development
elements and drive global consistency across development programs."
INC Research established a dedicated business unit for delivery of the FSP
services to Astellas, allowing for independent, cross-functional resource
management and training of Company staff committed to the partnership. An
executive governance structure has been implemented for management of the
relationship, with plans to leverage key metrics to drive decision making and
ensure continuous improvement across the alliance. Success will be measured
based on operational delivery, effective collaboration and process and
technology innovation.
INC Research is among the pioneers involved in development of the FSP model,
providing more than a decade of FSP experience and the expertise of hundreds of
dedicated and highly experienced FSP employees. The Company's FSP model uses
strategic commitment and performance-based measures to improve productivity in
key service areas for its biopharmaceutical customers. The end result is greater
cost predictability and delivery of consistent services across all protocols.
INC Research's FSP model has proven to reduce costs by up to 40 percent and
generate time savings of 10 to 20 percent over the course of a relationship.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development
programs of the highest integrity. Pharmaceutical and biotechnology companies
look to INC Research for a complete range of customized Phase I through Phase IV
programs in all therapeutic areas and innovative pediatric and women's health
trials. The Company's Trusted Process(®) methodology and therapeutic foresight
lead customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
Contact:
Lori Dorer, Media, (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1602975]
Unternehmensinformation / Kurzprofil:
Datum: 17.04.2012 - 15:04 Uhr
Sprache: Deutsch
News-ID 135919
Anzahl Zeichen: 4308
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 331 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Announces Multi-Year Strategic Clinical Development Alliance with Astellas"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
